Individualized Treatment Strategy for Depressive Disorder

被引:3
|
作者
Chen, Jun [1 ,2 ]
Hu, Shaohua [3 ]
机构
[1] Shanghai Jiao Tong Univ, Sch Med, Clin Res Ctr, Shanghai, Peoples R China
[2] Shanghai Jiao Tong Univ, Sch Med, Div Mood Disorders, Shanghai Mental Hlth Ctr, Shanghai, Peoples R China
[3] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Psychiat, Hangzhou, Peoples R China
关键词
Depressive disorders; Individualized treatment; Precision medicine; Genomics; Neural circuit; Artificial intelligence; MEASUREMENT-BASED CARE; NEUROTROPHIC FACTOR; PRECISION MEDICINE; MAJOR DEPRESSION; 2ND-GENERATION ANTIDEPRESSANTS; SEROTONIN TRANSPORTER; ANXIETY TREATMENTS; CANADIAN NETWORK; CONTROLLED-TRIAL; BRAIN;
D O I
10.1007/978-981-32-9271-0_12
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The goal of treatment for depressive disorders is complete remission of depressive symptoms with full recovery of social function and prevention of recurrence. However, a large proportion of patients do not experience symptomatic remission after the initial treatment, with even lower rates of remission in the longer treatment term. The main objective of individualized treatment applied in psychiatry is to improve precision in disease diagnosis, prognosis, treatment choices, and treatment response. Diverse approaches and techniques, such as genomics, epigenomics, other omics, neural circuit, and artificial intelligence are related to precision psychiatry. Using biology and computational psychiatry tools to find potential biomarkers, and based on precision psychiatry, patients considered to belong to the same endophenotype will be possible to receive biomarkers-based treatment and better prognosis. Especially in the choice of intervention, individualized treatment should be considered. In this review, we present the development of precise treatment in depressive disorders and introduce advances in several domains toward precision medicine and individualized treatment. We pay particular attention to biomarkers and the development of new technologies in depressive disorders, which will help disease complete remission and functional recovery, seek better lives for patients suffered with depressive disorders.
引用
收藏
页码:219 / 232
页数:14
相关论文
共 50 条
  • [41] Persistence of antidepressant treatment for depressive disorder in Taiwan
    Wu, Chi-Shin
    Shau, Wen-Yi
    Chan, Hung-Yu
    Lai, Mei-Shu
    GENERAL HOSPITAL PSYCHIATRY, 2013, 35 (03) : 279 - 285
  • [42] Psychopharmacologic treatment of pediatric major depressive disorder
    Khrista Boylan
    Soledad Romero
    Boris Birmaher
    Psychopharmacology, 2007, 191 : 27 - 38
  • [43] Anticonvulsants in the Treatment of Major Depressive Disorder: An Overview
    Vigo, Daniel V.
    Baldessarini, Ross J.
    HARVARD REVIEW OF PSYCHIATRY, 2009, 17 (04) : 231 - 241
  • [44] Vortioxetine: a New Treatment for Major Depressive Disorder
    Connolly, K. Ryan
    Thase, Michael E.
    EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (03) : 421 - 431
  • [45] Escitalopram for treatment of major depressive disorder in adults
    Llorca, PM
    Brousse, G
    Schwan, R
    ENCEPHALE-REVUE DE PSYCHIATRIE CLINIQUE BIOLOGIQUE ET THERAPEUTIQUE, 2005, 31 (04): : 490 - 501
  • [46] Treatment of a first depressive episode in bipolar disorder
    Pringuey, D.
    Cherikh, F.
    Tible, O.
    Giordana, B.
    ENCEPHALE-REVUE DE PSYCHIATRIE CLINIQUE BIOLOGIQUE ET THERAPEUTIQUE, 2010, 36 : S27 - S33
  • [47] Updates and Trends in the Treatment of Major Depressive Disorder
    Papakostas, George I.
    Ionescu, Dawn F.
    JOURNAL OF CLINICAL PSYCHIATRY, 2014, 75 (12) : 1419 - 1421
  • [48] CURRENT DIRECTIONS IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER
    Schutter, D.
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2016, 50 : 40 - 41
  • [49] The efficacy of vortioxetine for the treatment of major depressive disorder
    Dhir, Ashish
    Sarvaiya, Jayrajsinh
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2014, 14 (12) : 1349 - 1363
  • [50] Editorial: CBASP in the Treatment of Persistent Depressive Disorder
    Wiersma, Jenneke
    Klein, Philipp
    Schramm, Elisabeth
    Furukawa, Toshi
    Favorite, Todd
    FRONTIERS IN PSYCHIATRY, 2021, 12